Ontology highlight
ABSTRACT:
SUBMITTER: Gambacorti-Passerini C
PROVIDER: S-EPMC5947833 | biostudies-literature | 2018 May
REPOSITORIES: biostudies-literature
Gambacorti-Passerini Carlo C Orlov Sergey S Zhang Li L Braiteh Fadi F Huang Huiqiang H Esaki Taito T Horibe Keizo K Ahn Jin-Seok JS Beck Joseph T JT Edenfield William Jeffrey WJ Shi Yuankai Y Taylor Matthew M Tamura Kenji K Van Tine Brian A BA Wu Shang-Ju SJ Paolini Jolanda J Selaru Paulina P Kim Tae Min TM
American journal of hematology 20180208 5
Crizotinib, an inhibitor of anaplastic lymphoma kinase (ALK), MET, and ROS1, is approved for treatment of patients with ALK-positive or ROS1-positive advanced non-small-cell lung cancer (NSCLC). However, ALK rearrangements are also implicated in other malignancies, including anaplastic large-cell lymphoma and inflammatory myofibroblastic tumors (IMTs). In this ongoing, multicenter, single-arm, open-label phase 1b study (PROFILE 1013; NCT01121588), patients with ALK-positive advanced malignancies ...[more]